Scholarlink

<p>Brain ischemia is a major global cause of disability, frequently leading to psychoneurological issues. This study investigates the effects of 4-aminopyridine (4-AP) on anxiety, cognitive impairment, and potential underlying mechanisms in a mouse model of medial prefrontal cortex (mPFC) ischemia. Mice with mPFC ischemia were treated with normal saline (NS) or different doses of 4-AP (250, 500, and 1000&#xa0;µg/kg) for 14 consecutive days. The open field test, elevated plus maze, Barnes maze, and novel object recognition test were used to perform a series of behavioral assessments to evaluate anxiety as well as spatial and episodic memory. Serum corticosterone levels and changes in oxidative stress markers (MDA, SOD, GPx, and TAC) were measured by ELISA. Inflammatory and apoptotic markers (p-P38, NF-κB, IL-1β, TNF-α, p-PI3K, p-AKT, Caspase-3, BAX, and BCL2) were analyzed via western blotting. Results showed that mPFC ischemia induced anxiety-like behavior and disrupted both recognition and spatial memory at the behavioral level. Additionally, ischemia increased serum corticosterone levels, elevated oxidative stress, and upregulated inflammatory and apoptotic markers. However, 4-AP at the highest dose significantly mitigated these behavioral and molecular deficits. These findings suggest that 4-AP alleviates anxiety-like behavior and cognitive impairment associated with mPFC ischemia, possibly through modulation of corticosterone, oxidative stress, inflammation, and apoptotic signaling pathways.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

4-aminopyridine exerts anxiolytic and pro-cognitive effects in mice model of medial prefrontal cortex ischemia

  • 期刊论文

  • 发表日期：

    2025年9月10日

查看全文
  • Esmaeil Imani-Almas,
  • Javad Mahmoudi,
  • Mehdi Farhoudi,
  • Saeed Sadigh-Eteghad,
  • Abbas Ebrahimi-Kalan

摘要

Brain ischemia is a major global cause of disability, frequently leading to psychoneurological issues. This study investigates the effects of 4-aminopyridine (4-AP) on anxiety, cognitive impairment, and potential underlying mechanisms in a mouse model of medial prefrontal cortex (mPFC) ischemia. Mice with mPFC ischemia were treated with normal saline (NS) or different doses of 4-AP (250, 500, and 1000 µg/kg) for 14 consecutive days. The open field test, elevated plus maze, Barnes maze, and novel object recognition test were used to perform a series of behavioral assessments to evaluate anxiety as well as spatial and episodic memory. Serum corticosterone levels and changes in oxidative stress markers (MDA, SOD, GPx, and TAC) were measured by ELISA. Inflammatory and apoptotic markers (p-P38, NF-κB, IL-1β, TNF-α, p-PI3K, p-AKT, Caspase-3, BAX, and BCL2) were analyzed via western blotting. Results showed that mPFC ischemia induced anxiety-like behavior and disrupted both recognition and spatial memory at the behavioral level. Additionally, ischemia increased serum corticosterone levels, elevated oxidative stress, and upregulated inflammatory and apoptotic markers. However, 4-AP at the highest dose significantly mitigated these behavioral and molecular deficits. These findings suggest that 4-AP alleviates anxiety-like behavior and cognitive impairment associated with mPFC ischemia, possibly through modulation of corticosterone, oxidative stress, inflammation, and apoptotic signaling pathways.

Graphical abstract